Enlivex Therapeutics (ENLV) announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy ...
Zacks Small Cap Research on MSN
CYCN: Positive feedback from FDA sets stage for phase 2 trial of CYC-126 in 2H26
By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Business Update Positive Regulatory Feedback Supports Phase 2 Trial Initiation in 2H26 On February 17, 2026, Cyclerion Therapeutics, ...
SAN DIEGO, Sept. 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ...
ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study ...
Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 ...
TEL AVIV, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal ...
Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second ...
LONDON--(BUSINESS WIRE)--Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 ...
LAWRENCEVILLE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial ...
Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results